Over the past few years, cancer therapy with immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 axis has shown encouraging results in multiple cancer types, including HNSCC and OSCC [11,12]. This evidence concerns the gene CD274 and cancer.